Executive SummaryD.C. Circuit Court upholds April 1989 ITC ruling dismissing Amgen complaint that Chugai's importation of erythropoietin into the U.S. constitutes an unfair trade practice. The appeals court also affirmed an earlier ITC decision that found the importation of EPO by Chugai did not infringe Amgen's patent.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.